Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,449 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
Weber T, Bötticher B, Arndt MA, Mier W, Sauter M, Exner E, Keller A, Krämer S, Leotta K, Wischnjow A, Grosse-Hovest L, Strumberg D, Jäger D, Gröne HJ, Haberkorn U, Brem G, Krauss J. Weber T, et al. Among authors: keller a. Cancer Lett. 2016 Oct 28;381(2):296-304. doi: 10.1016/j.canlet.2016.08.007. Epub 2016 Aug 11. Cancer Lett. 2016. PMID: 27524505
An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo.
Kiesgen S, Arndt MAE, Körber C, Arnold U, Weber T, Halama N, Keller A, Bötticher B, Schlegelmilch A, Liebers N, Cremer M, Herold-Mende C, Dyckhoff G, Federspil PA, Jensen AD, Jäger D, Kontermann RE, Mier W, Krauss J. Kiesgen S, et al. Among authors: keller a. Cancer Lett. 2015 Feb 1;357(1):364-373. doi: 10.1016/j.canlet.2014.11.054. Epub 2014 Nov 27. Cancer Lett. 2015. PMID: 25434798
High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
Weber T, Bötticher B, Mier W, Sauter M, Krämer S, Leotta K, Keller A, Schlegelmilch A, Grosse-Hovest L, Jäger D, Haberkorn U, Arndt MA, Krauss J. Weber T, et al. Among authors: keller a. Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):489-98. doi: 10.1007/s00259-015-3175-6. Epub 2015 Sep 4. Eur J Nucl Med Mol Imaging. 2016. PMID: 26341366
Generation of “LYmph Node Derived Antibody Libraries” (LYNDAL) for selecting fully human antibody fragments with therapeutic potential.
Diebolder P, Keller A, Haase S, Schlegelmilch A, Kiefer JD, Karimi T, Weber T, Moldenhauer G, Kehm R, Eis-Hübinger AM, Jäger D, Federspil PA, Herold-Mende C, Dyckhoff G, Kontermann RE, Arndt MA, Krauss J. Diebolder P, et al. Among authors: keller a. MAbs. 2014 Jan-Feb;6(1):130-42. doi: 10.4161/mabs.27236. MAbs. 2014. PMID: 24256717 Free PMC article. Clinical Trial.
Advanced Critical Care Techniques in the Field.
Powell E, Keller AP, Galvagno SM Jr. Powell E, et al. Among authors: keller ap. Crit Care Clin. 2024 Jul;40(3):463-480. doi: 10.1016/j.ccc.2024.03.003. Epub 2024 Apr 17. Crit Care Clin. 2024. PMID: 38796221 Review.
Prediction of diagnosis and diastolic filling pressure by AI-enhanced cardiac MRI: a modelling study of hospital data.
Lehmann DH, Gomes B, Vetter N, Braun O, Amr A, Hilbel T, Müller J, Köthe U, Reich C, Kayvanpour E, Sedaghat-Hamedani F, Meder M, Haas J, Ashley E, Rottbauer W, Felbel D, Bekeredjian R, Mahrholdt H, Keller A, Ong P, Seitz A, Hund H, Geis N, André F, Engelhardt S, Katus HA, Frey N, Heuveline V, Meder B. Lehmann DH, et al. Among authors: keller a. Lancet Digit Health. 2024 Jun;6(6):e407-e417. doi: 10.1016/S2589-7500(24)00063-3. Lancet Digit Health. 2024. PMID: 38789141 Free article.
2,449 results